MCK — McKesson Corporation

The market is bullish because McKesson beat Q1 FY27 adjusted EPS by $0.29 ($9.93 vs. $9.64), grew revenue 8% to $105.4B, and raised full-year adjusted EPS guidance. About 25 of 31 covering analysts rate it Buy/Strong Buy, the 2026-08-27 price is near the upper end of its 52-week range, and the average 12-month target of $971.63 implies roughly 9% upside from $890.51.

Revenue growth has been consistently strong: +7.7% YoY in Q1 FY27, +10-11% in the prior two quarters, and +23% in Q1 FY26 on an easier comparison. Operating margin remains range-bound around 1.0-2.3%, with Q1 FY27 at 1.25%, so the story is volume-driven distribution rather than margin expansion. GAAP net income fell YoY in Q1 FY27 (EPS $5.15 vs. $6.25) due to one-off and other items, but adjusted EPS rose 20% to $9.93 and guidance was raised - the underlying earnings trajectory is inflecting up, even though reported GAAP is noisy.

At $890.51 on 2026-08-27, TTM P/E is 23.7x, below the 5-year average of 25.65x. On FY27 consensus EPS of $44.62, forward P/E is about 20.0x. The reported PEG of 0.48 looks very cheap, but normalized forward growth of roughly 15% makes it more like 1.3-1.5x growth. Price/sales of 0.25x is slightly above the 5-year average of 0.22x. Overall, valuation is fair-to-slightly-attractive relative to McKesson's own history, not stretched.

The market is paying about 20x forward earnings for a company that just raised guidance and is buying back stock aggressively, so solid execution is largely but not fully priced in. If FY27 EPS reaches the upper end of $45.00 and the Wellverse separation is received as a value unlock, the multiple could re-rate toward the historical mid-25x range. If guidance slips or separation execution disappoints, the low-end analyst target of $845 and the sub-$800 area are realistic downside markers.

As of 2026-08-27, RSI(14) was 57.7, a neutral-positive reading and not overbought. Price was 2.57% above its 20-day SMA, 7.31% above its 50-day SMA, and 5.82% above its 200-day SMA, with the stock at $890.51 versus a 52-week range of $679.65-$999. The trend is up but modestly extended short-term; momentum traders might wait for a pullback toward the 20-day SMA, while longer-term holders remain in a valid uptrend.

• Stabilizing or declining interest rates support McKesson's debt-funded buybacks and Wellverse separation financing.
• Inelastic pharmaceutical demand and an aging population provide defensive, recurring revenue.
• Accelerating oncology and specialty biologic adoption is shifting the product mix toward higher-margin, higher-growth areas.
• Pharmacy customer credit risk, including retail pharmacy bankruptcies, can produce bad-debt swings.
• Regulatory and legal overhangs from opioid-related claims and drug-pricing policy remain sector-wide risks.

• Q2 FY27 earnings expected in early November 2026 and any further FY27 guidance raise.
• Wellverse Medical-Surgical separation milestones: regulatory clearances, spin-off tax treatment, and debt allocation.
• Continued heavy share repurchases ($2.5B in Q1 FY27 alone) and the 15% dividend increase.
• Sustained oncology/multispecialty volume growth in the North American Pharmaceutical segment.

• Negative stockholders' equity of -$4.24B and long-term debt of $8.43B at 6/30/26 increase financial leverage despite strong cash flow.
• Very thin gross and operating margins (3.6% and 1.6%) leave earnings sensitive to contract renegotiations and generic/drug-price deflation.
• Wellverse separation execution risk, including stranded costs, tax leakage, or unexpected capital needs.
• Customer credit events such as pharmacy-chain bankruptcies, plus ongoing opioid-litigation exposure, could hit earnings.

McKesson is a high-quality, defensive healthcare compounder with a wide distribution moat, 31.5% ROIC, growing specialty-drug exposure, and a shareholder-friendly capital-allocation machine. As of 2026-08-27 at $890.51, the stock is roughly fairly valued with a modest edge to upside - my fair-value estimate is about $1,004 - but balance-sheet strain and separation execution risk argue for buying on weakness rather than chasing momentum. This is analysis, not personalized investment advice.

Calculated by applying a 22.5x forward P/E to FY27 consensus EPS of $44.62; 22.5x is roughly a 12% discount to McKesson's 5-year average P/E of 25.65x to reflect thin margins, negative book equity, and separation execution risk. The result triangulates between the current ~20x forward multiple and the $971.63 analyst consensus target, yielding about $1,004.